About Medizinische Univ Graz | Frauenheilkunde & Geburtshilfe
- Top Sponsors
- Top Collaborators
- Trials By Phase
- Recruitment Status
- Top Conditions
- Intervention Types
- Top Intervention Names
- Trials By Gender
Lead Sponsor
# Trials
Clinical Trials at Medizinische Univ Graz | Frauenheilkunde & Geburtshilfe
During the past decade, Medizinische Univ Graz | Frauenheilkunde & Geburtshilfe conducted 2 clinical trials. In the 10-year time frame, 2 clinical trials started and 0 clinical trials were completed, i.e. on
average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 2 clinical trials started and 0 clinical trials were completed. i.e. 0%
of trials that started reached the finish line.
Trials List
Trail ID
Brief Title
Start Date
Completion Date
Status
Enrollment
FEM-PrEP (Truvada®): Study to Assess the Role of Truvada® in Preventing HIV Acquisition in Women
2009-05-01
2013-01-01
Completed
2,120
Safety and Effectiveness of Tenofovir Gel in the Prevention of Human Immunodeficiency Virus (HIV-1) Infection in Women and the Effects of Tenofovir Gel on the Incidence of Herpes Simplex Virus (HSV-2) Infection
2011-10-01
2014-08-01
Completed
2,059
A Trial in Subjects Suspected to Have Tuberculosis, Comparing the Diagnostic Performance of C-Tb to QuantiFERON®, in Combination With a Safety Assessment of C-Tb Versus Tuberculin PPD RT23 SSI
2012-09-01
2014-09-01
Completed
1,190
Study to Identify Factors Influencing Access of Pregnant Women and Their Infants to Local Healthcare Systems
2012-11-01
2015-01-01
Completed
3,243
Safety Study Investigating if Concomitant Injections of C-Tb and 2 T.U Tuberculin Affect Induration Responses
2013-10-01
2014-09-01
Completed
456
The Evidence for Contraceptive Options and HIV Outcomes Trial
2015-12-14
2018-10-31
Completed
7,830
Evaluating the Safety and Immunogenicity of HIV Clade C DNA Vaccine and MF59- or AS01B-Adjuvanted Clade C Env Protein Vaccines in Various Combinations in Healthy, HIV-Uninfected Adults
2016-12-07
2020-02-12
Completed
334
Clinical Trials Sponsors and Collaborators
Clinical Trials Conditions at Medizinische Univ Graz | Frauenheilkunde & Geburtshilfe
According to Clinical.Site data, the most researched conditions in "Medizinische Univ Graz | Frauenheilkunde & Geburtshilfe" are
"Hot Flashes" (2 trials), "Vasomotor Symptoms Associated With Menopause" (1 trials) and "Vasomotor Symptoms Caused by Adjuvant Endocrine Therapy in Women With, or at High Risk for Developing Hormone-receptor Positive Breast Cancer" (1 trials). Many other conditions were trialed in "Medizinische Univ Graz | Frauenheilkunde & Geburtshilfe" in a lesser frequency.
Clinical Trials Intervention Types at Medizinische Univ Graz | Frauenheilkunde & Geburtshilfe
Most popular intervention types in "Medizinische Univ Graz | Frauenheilkunde & Geburtshilfe" are "Drug" (2 trials). Other intervention types were less common.
The name of intervention was led by "Elinzanetant (BAY3427080)" (2 trials) and "Placebo" (2 trials). Other intervention names were less common.
Clinical Trials Genders at Medizinische Univ Graz | Frauenheilkunde & Geburtshilfe
The vast majority of trials in "Medizinische Univ Graz | Frauenheilkunde & Geburtshilfe" are
2 trials for "Female" genders.
Clinical Trials Status at Medizinische Univ Graz | Frauenheilkunde & Geburtshilfe
Currently, there are NaN active trials in "Medizinische Univ Graz | Frauenheilkunde & Geburtshilfe".
undefined are not yet recruiting,
1 are recruiting,
1 are Active, not recruiting,
and undefined are Enrolling by invitation.
In total, there were undefined completed trials in Medizinische Univ Graz | Frauenheilkunde & Geburtshilfe,
undefined suspended trials,
and undefined terminated clinical trials to date.
Out of the total trials that were conducted in Medizinische Univ Graz | Frauenheilkunde & Geburtshilfe, 0 "Phase 1"
clinical trials were conducted, 0 "Phase 2" clinical
trials and 2 "Phase 3" clinical trials were conducted as
well. "Phase 4" trials included 0 trials, and there were
also 0 trials that are defined as “Not Applicable".